Related Experiment Videos
Summary
Leuprorelin acetate depot effectively thinned the endometrium in women with uterine bleeding, improving menstrual outcomes before endometrial ablation. This hormone suppression pretreatment is recommended for better surgical results.
Area of Science:
- Gynecology
- Reproductive Medicine
- Surgical Oncology
Background:
- Intractable uterine bleeding affects pre- and peri-menopausal women with completed family planning.
- Endometrial ablation is a surgical option for managing uterine bleeding.
- Pretreatment strategies can optimize outcomes for endometrial ablation.
Purpose of the Study:
- To evaluate the efficacy of leuprorelin acetate monthly depot as a pretreatment before endometrial ablation.
- To assess the impact of leuprorelin acetate on endometrial thickness and clinical menstrual response.
Main Methods:
- A clinical trial involving 94 pre- or peri-menopausal patients with intractable uterine bleeding.
- Administration of leuprorelin acetate 3.75 mg monthly depot for two cycles prior to endometrial ablation.
- Measurement of endometrial thickness before treatment and before surgery (two weeks post-second injection).
Main Results:
- A mean endometrial flattening of 4.0 +/- 4.1 mm was observed.
- Sufficient endometrial thinning (>50% decrease) was achieved in 91.3% of patients.
- Positive clinical response, including amenorrhea or hypomenorrhea, was noted in 83% of patients at six months.
Conclusions:
- Hormone-suppressive pretreatment with leuprorelin acetate depot is effective prior to hysteroscopic endometrial ablation.
- This pretreatment leads to significant endometrial thinning and improved clinical outcomes.
- Scheduling surgery approximately two weeks after the second leuprorelin acetate injection is recommended.